Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Chesley Taft & Associates LLC

Chesley Taft & Associates LLC raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 184.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,237 shares of the biopharmaceutical company’s stock after purchasing an additional 802 shares during the period. Chesley Taft & Associates LLC’s holdings in Regeneron Pharmaceuticals were worth $955,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Salomon & Ludwin LLC acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $31,000. Board of the Pension Protection Fund acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $31,000. Caitlin John LLC purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $34,000. Finally, Berbice Capital Management LLC grew its stake in Regeneron Pharmaceuticals by 300.0% in the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 60 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $737.71 on Monday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The company’s fifty day moving average is $764.67 and its two-hundred day moving average is $708.06. The firm has a market cap of $77.99 billion, a PE ratio of 17.75, a price-to-earnings-growth ratio of 1.98 and a beta of 0.40. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The business had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same period in the prior year, the firm posted $12.07 EPS. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were paid a dividend of $0.94 per share. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date was Friday, February 20th. Regeneron Pharmaceuticals’s payout ratio is currently 9.05%.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This represents a 46.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.53, for a total transaction of $77,853.00. Following the completion of the transaction, the director owned 17,803 shares in the company, valued at $13,860,169.59. The trade was a 0.56% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 5,274 shares of company stock valued at $4,142,738. 7.02% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of recent analyst reports. Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday. Zacks Research downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. BMO Capital Markets upped their target price on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a research note on Thursday, December 4th. Wells Fargo & Company increased their target price on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a research report on Monday, February 2nd. Finally, Guggenheim raised their price target on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $802.27.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.